Randomized study of early hospital discharge following autologous blood SCT: Medical outcomes and hospital costs

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 549-555

  Faucher, C ^a   Le Corroller Soriano, A G ^b,c   Esterni, B ^a   Vey, N ^a,c,d   Stoppa, A M ^a   Chabannon, C ^a,c,d   Mohty, M ^e   Michallet, M ^f   Bay, J O ^g   Genre, D ^a,h   Maraninchi, D ⁱ   Viens, P ^a,c,h   Moatti, J P ^b,c   Blaise, D ^a,c,d  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔTEL DIEU   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g CENTRE JEAN PERRIN   (France)

^h Centre d'Investigation Clinique (CIC) 9502   (France)

ⁱ INSTITUT NATIONAL DU CANCER   (France)

Author keywords

auto SCT; cost; outpatient

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ADULT; AGED; APLASIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER STAGING; CAREGIVER SUPPORT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HOME CARE; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT DURATION; TREATMENT PLANNING; WHOLE BODY RADIATION;

ADULT; COSTS AND COST ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT DISCHARGE; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84859473217     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.126     Document Type: Article

References (23)

1. Le Corroller AG, Moatti JP. The economic evaluation of hematopoietic growth factors in high dose chemotherapy. Anti Cancer Drugs 1998; 9: 917-924.
2. Smith AM, Keating A. Peripheral blood progenitor cell transplantation: clinical, practical and economic considerations. J Hematother 1994; 3: 331-348.
3. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AAPM, Rutten FFH. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994; 30A: 457-459. (Pubitemid 24171950)
4. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F et al. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized controlled trial. Ann Intern Med 1997; 126: 600-607. (Pubitemid 27172186)
5. Anastasia A, Giglio F, Mazza R, Sarina B, Todisco E, Bramanti S et al. Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. Leuk Lympho-ma 2009; 50: 80-84.
6. Fernandez-Aviles F, Carreras E, Urbano-Ispizua A, Rovira M, Martinez C, Gaya A et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006; 24: 4855-4861. (Pubitemid 46630912)
7. Ferrara F, Palmieri S, Viola A, Copia C, Schiavone EM, De Simone M et al. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma. Hematol J 2004; 5: 222-226. (Pubitemid 38931327)
8. Freeman M, Vose J, Bennett C, Anderson J, Kessinger A, Turner K et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant 1999; 24: 679-684. (Pubitemid 29446145)
9. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002; 30: 741-748. (Pubitemid 36004301)
10. Gluck S, des Rochers C, Cano C, Dorreen M, Germond C, Gill K et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997; 20: 431-434. (Pubitemid 27434889)
11. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20: 445-450. (Pubitemid 27434891)
12. Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C et al. Outpatient autologous hemato-poietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006; 85: 723-729. (Pubitemid 44251818)
13. McDiarmid S, Hutton B, Atkins H, Bence-Bruckler I, Bredeson C, Sabri E et al. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010; 45: 1220-1226.
14. Meisenberg BR, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: 11-17. (Pubitemid 27020552)
15. Peters WP, Ross M, Vredenburgh J, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21(supl 7): 25-31. (Pubitemid 24300030)
16. Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17: 2811-2818. (Pubitemid 29415239)
17. Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000; 26: 389-395. (Pubitemid 30649554)
18. Mehta J, Dulley FL. Outpatient or inpatient stem cell transplantation: patria est ubicunque est bene? Leuk Lymphoma 2009; 50: 3-5.
19. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology (Huntingt) 2000; 14: 171-185; discussion 85-86, 91-92.
20. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21(Suppl 7): 25-31. (Pubitemid 24300030)
21. Rovira M. Outpatient management of autologous haematopoietic cell transplantation: the Barcelona experience. Presse Med 2004; 33: 479-481. (Pubitemid 38489875)
22. Westermann AM, Holtkamp MM, Linthorst GA, van Leeuwen L, Willemse EJ, van Dijk WC et al. At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hemato-logical malignancies. Ann Oncol 1999; 10: 511-517. (Pubitemid 29305427)
23. Stiff P, Mumby P, Miler L, Rodriguez T, Parthswarthy M, Kiley K et al. Autologous hematopoietic stem cell transplants that utilize total body irradiation can safely be carried out entirely on an outpatient basis. Bone Marrow Transplant 2006; 38: 757-764. (Pubitemid 44756446)